Cargando…

MYBL2 mRNA expression as a potential biomarker of therapeutic response to genotoxic treatments in myelodysplastic syndrome

Detalles Bibliográficos
Autores principales:	Bayley, Rachel, Blakemore, Daniel, García, Paloma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331017/ https://www.ncbi.nlm.nih.gov/pubmed/30680058 http://dx.doi.org/10.18632/oncotarget.26477

Ejemplares similares

MYBL2 and ATM suppress replication stress in pluripotent stem cells
por: Blakemore, Daniel, et al.
Publicado: (2021)

Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming
por: Ward, Carl, et al.
Publicado: (2018)

Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A Case-Control Study
por: Liu, Baoshan, et al.
Publicado: (2017)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

mRNA vaccine: a potential therapeutic strategy
por: Wang, Yang, et al.
Publicado: (2021)

Bioinformatics gene analysis of potential biomarkers and therapeutic targets of osteoarthritis associated myelodysplastic syndrome
por: Xin, Peicheng, et al.
Publicado: (2023)

Impairment of FOS mRNA Stabilization Following Translation Arrest in Granulocytes from Myelodysplastic Syndrome Patients
por: Feng, Xiaomin, et al.
Publicado: (2013)

Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes
por: Diamantopoulos, P, et al.
Publicado: (2017)

mRNA Innovates the Vaccine Field
por: Pardi, Norbert
Publicado: (2021)

Recent Updates on mRNA Vaccines
por: Sydow, Emily, et al.
Publicado: (2022)

mRNA Metabolism in Health and Disease
por: Romão, Luísa
Publicado: (2022)

MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer
por: Jiao, Meng, et al.
Publicado: (2022)

A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer
por: Liu, Qian, et al.
Publicado: (2021)

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia
por: Clarke, M, et al.
Publicado: (2013)

A 4D view on mRNA
por: Smith, Carlas, et al.
Publicado: (2015)

Cardiovascular disease, inflammation, and mRNA stability
por: Herman, Allison B., et al.
Publicado: (2018)

LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis
por: Mu, Xiangyu, et al.
Publicado: (2022)

Myelodysplastic Syndrome: Riding the Crest of the Wave
por: Ramos, Fernando
Publicado: (2022)

Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
por: Asrani, Kirtika H., et al.
Publicado: (2018)

MYB/MYBL1::QKI fusion-positive diffuse glioma
por: Suh, Ye Yoon, et al.
Publicado: (2023)

CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
por: Barrón, Eira Valeria, et al.
Publicado: (2015)

mRNA Covid-19 Vaccines in Pregnant Women
por: Riley, Laura E.
Publicado: (2021)

Expression of Concern: Impairment of FOS mRNA Stabilization Following Translation Arrest in Granulocytes from Myelodysplastic Syndrome Patients
Publicado: (2023)

Active mRNA degradation by EXD2 nuclease elicits recovery of transcription after genotoxic stress
por: Sandoz, Jérémy, et al.
Publicado: (2023)

Potential Salivary mRNA Biomarkers for Early Detection of Oral Cancer
por: Oh, Su Young, et al.
Publicado: (2020)

mRNA therapeutics in cancer immunotherapy
por: Beck, Jan D., et al.
Publicado: (2021)

The Delivery of mRNA Vaccines for Therapeutics
por: Nitika,, et al.
Publicado: (2022)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Bronchial Epithelial Cell CC16 mRNA: Novel Asthma Biomarker or the Same Book with a New Cover?
por: Desai, Brinda, et al.
Publicado: (2022)

Cytotoxicity and Genotoxicity of Nanomaterials
por: Valdiglesias, Vanessa
Publicado: (2022)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Targeting age-related inflammation in myelodysplastic syndromes
por: Mei, Yang, et al.
Publicado: (2018)

LncRNA-mRNA co-expression analysis discovered the diagnostic and prognostic biomarkers and potential therapeutic agents for myocardial infarction
por: Zhang, Xiaocong, et al.
Publicado: (2021)

Nonsense-Mediated mRNA Decay: Pathologies and the Potential for Novel Therapeutics
por: Pawlicka, Kamila, et al.
Publicado: (2020)

MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy
por: Heinrichs, Stefan, et al.
Publicado: (2013)

Coronavirus disease 2019 and mRNA vaccines: what’s next – miRNA?
por: Lee, Joon Kee, et al.
Publicado: (2022)

Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients
por: Jia, Yongxu, et al.
Publicado: (2019)

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
por: Yoshikawa, Yuki, et al.
Publicado: (2022)

Detecting MYB and MYBL1 Fusion Genes in Tracheobronchial Adenoid Cystic Carcinoma by Targeted RNA-Sequencing
por: Pei, Jianming, et al.
Publicado: (2019)

Approved mRNA Vaccines for SARS-CoV-2
por: Faiman, Beth
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q7qkfavpkor9l6hpmemb5kahev